| Literature DB >> 31351758 |
Rishi K Patel1, Alice M Moore2, Susan Piper3, Mark Sweeney4, Eromona Whiskey5, Graham Cole4, Sukhi S Shergill6, Carla M Plymen4.
Abstract
This review discusses the rare but potentially life-threatening cardiovascular side-effects of myocarditis and dilated cardiomyopathy associated with the use of Clozapine. The clinical presentation of these conditions is non-specific, making it difficult to both risk-stratify and identify patients who develop these consequences. This review aims to examine the proposed aetiologies, diagnostic approaches and subsequent management strategies of cardiotoxicity associated with clozapine use; offering guidance to psychiatrists and general physicians. Current evidence highlights the importance of accurate diagnosis to prevent premature and unnecessary cessation of clozapine. Guidance on monitoring and reintroduction of the drug is emerging and current practice recommends a combination of regular monitoring of biomarkers and imaging to make a diagnosis of cardiotoxicity although further work is needed to establish evidence-based guidelines.Entities:
Keywords: Cardiomyopathy; Myocarditis; Pharmacotherapy; Psychosis; Schizophrenia
Mesh:
Substances:
Year: 2019 PMID: 31351758 DOI: 10.1016/j.psychres.2019.112491
Source DB: PubMed Journal: Psychiatry Res ISSN: 0165-1781 Impact factor: 3.222